EP0876159A1 - Composition pour traiter les affections de la peau et procede de preparation de ladite composition - Google Patents

Composition pour traiter les affections de la peau et procede de preparation de ladite composition

Info

Publication number
EP0876159A1
EP0876159A1 EP97902196A EP97902196A EP0876159A1 EP 0876159 A1 EP0876159 A1 EP 0876159A1 EP 97902196 A EP97902196 A EP 97902196A EP 97902196 A EP97902196 A EP 97902196A EP 0876159 A1 EP0876159 A1 EP 0876159A1
Authority
EP
European Patent Office
Prior art keywords
weight
amount
composition
relative
complete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97902196A
Other languages
German (de)
English (en)
Inventor
Johannes Schreuder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemisch Adviesbureau Drs J C P Schreuder BV
Original Assignee
Chemisch Adviesbureau Drs J C P Schreuder BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemisch Adviesbureau Drs J C P Schreuder BV filed Critical Chemisch Adviesbureau Drs J C P Schreuder BV
Priority to EP97902196A priority Critical patent/EP0876159A1/fr
Publication of EP0876159A1 publication Critical patent/EP0876159A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Definitions

  • the invention relates to a composition for treating skin affections, to a process for its preparation, and to the application of said composition.
  • the invention relates to a multifunctional composition for the treatment of chapped, sore and/or inflamed skin parts such as lips, nose opening edges, eyelids and the like, while such composition does not contain ingredients which may disturb the biological equilibrium of said skin part.
  • composition of the invention heals, relieves and softens chapped, sore or inflamed lips, nose opening edges, eyelids and the like, affected by a Herpes Simplex virus type, such as fever blister and/or affections by winter weather and/or intensive sunshine.
  • compositions have already been proposed for this purpose n the course of the last decade.
  • prior art compositions have the disadvantage that they cause a burning, irritated and/or inflamed feeling, usually caused by constituents which significantly disturb the biological equilibrium of the affected skin parts .
  • said prior art compositions usually d d not relieve the irritation or even pam, and certainly did not heal the affected skin in an efficient way.
  • one object of the present invention is to provide a multifunctional composition for the treatment of chapped, sore and/or inflamed skin parts such as lips, nose opening edges, eyelids and the like, which during application does not cause a burning, irritated and/or inflamed feeling and which facilitate an almost immediate relief and healing, and the constituents of which do not disturb the biological equilibrium of the affected sk n parts.
  • Another object of the present invention is to provide a process for the preparation of said composition.
  • the present invention provides a multifunctional composition for the treatment of chapped, sore and/or inflamed skin parts such as lips, nose opening edges, eyelids and the like, characterised by at least the following ingredients :
  • An oil fraction comprising straight or branched paraffinic oils, having from 10 to 60 carbon atoms in the chain, and preferably from 15 to 25 carbon atoms, in an amount of from 10 to 60 % by weight, and preferably from 15 to 25 % by weight, relative to the weight of the complete composition, having a boiling range between 100 and 500°C at atmospheric pressure and a viscosity of preferably at most 35 mm 2 /s, preferably of at most 30 mm ⁇ /s, at 25°C, while the paraffinic oils may optionally be mixed with esters of higher natural fatty acids, which are preferably unsaturated, and of higher natural aliphatic alcohols, which are preferably unsaturated, of at most 20 carbon atoms in the chain, in an amount of from 0 to 2 % by weight, and preferably from 0.5 to 2 % by weight, relative to the weight of the complete composition;
  • n, m and p represent the same or different integers of from 0 to 20, under the condition that at least one of the symbols n, m and p has a value of from 5 to 20, preferably from 7 to 15, and wherein R represents the same or different saturated or unsaturated, and preferably the same unsaturated hydrocarbon residue, derived from vegetable or animal oil (e.g. Tagat TO) .
  • the weight ratio between the amount of mono- and/or diglycerides on the one hand and of the ethoxylated triglycerides on the other hand may vary from 10 to 100 parts by weight of mono- and/or diglycerides per part by weight of ethoxylated triglycerides and preferably from 15 to 50 parts by weight of mono- and/or diglycerides per part by weight of ethoxylated triglycerides, whereas the amount of the complete emulsifying system, relative to the weight of the complete composition, may vary from 0.5 to 3.5 % by weight and preferably from 2 to 3 % by weight, relative to the weight of the total composition.
  • Vitamin E or a derivative thereof which may easily provide vitamin E itself by conversion on the affected skin, such as Covitol (trademark), in an amount of from 0.1 to 5 % by weight, and preferably from 0.5 to 4 % by weight, and most preferably from 1 to 3 % by weight, relative to the weight of the total composition;
  • Methionine in the form of its L or D isomer or mixtures thereof, preferably L-methionine, or a derivative thereof which may easily provide methionine by conversion on the affected skin, in an amount of from 0.1 to 5 % by weight and preferably from 0.5 to 3 % by weight and most preferably from 1 to 2 % by weight, relative to the weight of the complete composition;
  • a pH regulating system to adjust the pH of a present aqueous phase including at least demineralized water and methionine, to be in the range of from 4.4 to 5.0 and more preferably from 4.5 to 4.9, comprising preferably citric acid, zinc carbonate and sodium hydroxide, or citric acid, zinc carbonate and potassium hydroxide, each of the components occurring n an amount of from 0.05 to 2.5 % by weight, relative to the weight of the complete composition.
  • citric acid, zinc carbonate and sodium hydroxide occur in amounts of from 0.5 to 2 % by weight, from 0.05 to 0.2 % by weight and from 0.5 to 1 % by weight, respectively, relative to the weight of the complete composition.
  • the pH of the final complete composition is adjusted by said pH regulating system to the range of from 4.8 to 5.1 with citric acid or sodium hydroxide.
  • a stabilizer consisting of at least one montmorillonite, the free oxygen sites of which are occupied by quaternary groups (quaternary modified montmorillonites) .
  • Such stabilizers which are preferably included are Bentone (trademark) or Propoloid (trademark) .
  • Said stabilizers are included in the composition in amounts of from 0.1 to 1.5 % by weight and preferably from 0.5 to 0.7 % by weight, relative to the weight of the complete composition.
  • demineralized water is used in amounts of from 65 to 75 % by weight, relative to the weight of the complete composition.
  • one or more secondary ingredients also can be present in the complete compositions, such as;..
  • esters of parahydroxy benzoic acid may occur in the oily phase as well as in the aqueous phase.
  • the methyl and/or the (iso)propyl ester is present in an amount of from 0.1 to 1 % by weight and most preferably in amounts from 0.5 to 0.7 % by weight, relative to the weight of the complete composition.
  • the preservatives occur in the aqueous phase in a total amount of from 0.3 to 0.4 % by weight;
  • (l) Glycerol in an amount of from 1 to 4 % by weight and more preferably from 1 to 3 % by weight.
  • a gel forming agent such as carraghenate, preferably consisting of a polysaccharide with sulphonic ac d residues, and preferably a gel forming agent of natural origin such as one derived from seaweeds .
  • the sulphonic acid residues have optionally been converted into salts or esters of glycol, propylen glycol and glycerol (resulting in the so-called modified carraghenates) .
  • the gel forming agent e. g. the carraghenates, n amounts of from 0.1 to 5 % by weight, relative to the weight of the complete composition and preferably from 0.5 to 2 % by weight, cause a gel structure m the final composition.
  • a complete composition shows a viscosity of 200 to 5000 mPa-s (centipoises) at 25°C, enabling an adequate application of the composition.
  • the carraghenate may be completely or partially replaced by alternative gel forming means, such as carboxy methyl cellulose, esterified by polyacrylic acid e. g Carbopol (trademark), or hydroxy ethyl cellulose, n amounts which provide the viscosity values in the above range.
  • (k) Perfume in an amount of from 0.1 to 2 % by weight, preferably 0.1 to 0.3 % by weight, relative to the weight of the complete composition. Examples of such perfumes are sage oil or jacaranda.
  • At least one protein obtainable from aqueous extraction of plants, such as aloe vera, in amounts of from 0.1 to 0.5 % by weight, relative to the weight of the complete composition, and preferably from 0.1 to 0.3 % by weight.
  • compositions according to the present invention as specified hereinbefore are characterized by a relatively low viscosity and high stability, which guarantees an easy application, without a 'greasy” feeling or stickiness, due to the fast penetration into the skin tissue, and moreover by a healing, relieving and softening activity.
  • Another aspect of the present invention is formed by a process for the preparation of the hereinbefore specified compositions .
  • the complete continuous oily phase is prepared in one or more steps of said process, composed of oil fractions, the optional esters of fatty acids and alcohols, the emulsifying system, the stabilizer, vitamin E or a derivative thereof and the optional preservative, wherein in one or more separate steps at least one dispersed aqueous phase is prepared, composed of demmeralized water, citric acid or a citrate, zinc carbonate and sodium or potassium hydroxide, methionine, glycerol, gel forming agent, protein, and preservative and perfume
  • composition according to the present invention is prepared by composing both phases and mixing them together at a temperature of 10 to 40°C, followed by additional stirring and homogenizing until an average particle size of the dispersed aqueous phase of at most 5 ⁇ and preferably smaller than 3 ⁇ is reached, while the pH of the final complete composition is adjusted within the range of from 4.8 to 5.1.
  • a first step the oil fraction, the optional esters of unsaturated fatty acids and alcohols, the emulsifying system and the stabilizer are mixed and homogenized at a temperature from 60 to 90°C, whereafter the homogeneous mixture is cooled back to a temperature of at most 30°C.
  • the cooled mixture is mixed in a second step with vitamin E or a derivative thereof which can easily be transformed nto said vitamin, and with the perfume, until a homogeneous mixture is obtained.
  • the aqueous phase is normally prepared at a temperature of from 10 to 40°C and preferably from 20 to 30°C by subsequent addition of demineralized water n an amount of about one third of the total amount n the final composition, of the citric acid, of zinc carbonate and of sodium or potassium hydroxide under gently stirring until complete dissolution.
  • the pH of the homogeneous solution is adjusted to the range of from 4.6 to 4.8 by addition of sodium or potassium hydroxide or citric acid.
  • the remainder of the desired total amount of water, methionine, glycerol, carraghenate, preservative and protein are added whereafter the pH is again adjusted to the range of from 4.5 to 4.8.
  • the finally obtained aqueous phase is added to the oily phase under stirring vigorously and subsequent homogenizing at a temperature in the range of from 10 to 40°C and preferably from 20 to 30°C, whereafter the pH of the complete dispersion, having dispersed aqueous phase particles cf an average size of at most 5 ⁇ , is in the range of from 4.9 to 5.1.
  • Another aspect of the present invention is formed by the application of the before specified composition, i. e. the treatment of the chapped, sore and/or inflamed skin of lips and nose opening edges, eyelids and the like, with the hereinbefore specified composition.
  • Such an application comprises a method being usual for said compositions, characterized by application and evenly spreading the composition on the skin area involved, in an amount of from 20 to 100 ml/m 2 skin area.
  • This treatment should preferably be performed 2 to 3 times a day.
  • paraffinic oil I boiling range 295-390°C
  • paraffinic oil II boiling range 290-500°C
  • Tegomuls SB (trademark) 2.280 kg
  • the homogeneous mixture is cooled to 30°C and mixed with
  • An aqueous phase is prepared by mixing together:
  • the pH of the aqueous solution is adjusted with either citric acid or sodium hydroxide to a pH of from 4.60 to 4.80, and
  • the batches III and IV are combined and mixed with the mixture of batches I and II under vigorously stirring and homogenzmg until an average particle size of the dispersed phase of 3 ⁇ is obtained, whereafter the pH of the complete composition was 5.0.
  • Example 1 a composition was prepared from the following ingredients:
  • paraffinic oil I 14.700 kg paraffinic oil II 3.200 kg mono- and diglycerides 2.100 kg
  • composition was prepared from the following ingredients:
  • compositions show a high stability and a fast healing, relieving and softening activity when applied on sore, chapped and/or inflamed skin of lips and nose opening edges .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet une composition multifonctionnelle pour le traitement de la peau gercée, endolorie et/ou enflammée. Cette composition comprend au moins les ingrédients suivants: (a) une fraction d'huile comprenant des huiles paraffiniques à chaînes droites ou ramifiées, comportant 10 à 60 atomes de carbones dans la chaîne; (b) un système d'émulsification comprenant essentiellement (b,i) des mono- et/ou diglycérides d'acides gras saturés et insaturés supérieurs, et (b,ii) des triglycérides éthoxylatés, estérifiés avec des acides gras; (c) de la vitamine E, ou un dérivé de cette dernière; (d) de la méthionine; (e) un système régulateur du pH; (f) un stabilisateur se composant de montmorillonite; (g) de l'eau à raison de 100 % en poids. L'invention traite également de la préparation et de l'utilisation de ladite composition.
EP97902196A 1996-01-23 1997-01-21 Composition pour traiter les affections de la peau et procede de preparation de ladite composition Withdrawn EP0876159A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97902196A EP0876159A1 (fr) 1996-01-23 1997-01-21 Composition pour traiter les affections de la peau et procede de preparation de ladite composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP96100928 1996-01-23
EP96100928 1996-01-23
PCT/EP1997/000269 WO1997026917A1 (fr) 1996-01-23 1997-01-21 Composition pour traiter les affections de la peau et procede de preparation de ladite composition
EP97902196A EP0876159A1 (fr) 1996-01-23 1997-01-21 Composition pour traiter les affections de la peau et procede de preparation de ladite composition

Publications (1)

Publication Number Publication Date
EP0876159A1 true EP0876159A1 (fr) 1998-11-11

Family

ID=8222427

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97902196A Withdrawn EP0876159A1 (fr) 1996-01-23 1997-01-21 Composition pour traiter les affections de la peau et procede de preparation de ladite composition

Country Status (4)

Country Link
EP (1) EP0876159A1 (fr)
AU (1) AU1593697A (fr)
NO (1) NO983215L (fr)
WO (1) WO1997026917A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919224A1 (fr) * 1997-10-20 1999-06-02 Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. L'huile à nettoyer le nez
ES2371026T3 (es) * 2001-10-19 2011-12-26 Atritech, Inc. Dispositivo de oclusión ajustable en la orejuela auricular izquierda.
AP2006003784A0 (en) * 2004-03-18 2006-10-31 Panacea Biotec Ltd Novel compositions for topical delivery
TWI473624B (zh) * 2009-09-14 2015-02-21 Shiseido Co Ltd D-methionine and its salts are used in the manufacture of methods for reducing the UV damage composition
FR2992188B1 (fr) * 2012-06-21 2014-11-28 Oreal Composition a effet matifiant comprenant des particules d'aerogels hydrophobes et un tensioactif non ionique oxyethylene
US11806427B2 (en) * 2014-09-17 2023-11-07 Alps South Europe, S.R.O. Topical composition containing antioxidants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138292A (fr) * 1978-06-30 1982-12-28 Johannes C.P. Schreuder Produit de decrassage des mains
JPS5916816A (ja) * 1982-07-16 1984-01-28 Lion Corp 外用組成物
US4721705A (en) * 1983-09-26 1988-01-26 Chemish Adviesbureau Drs. J.C.P. Schreuder B.V. Skin treatment compositions
EP0203211A1 (fr) * 1985-05-28 1986-12-03 Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. Composition pour le traitement des affections de la peau et procédé pour sa préparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9726917A1 *

Also Published As

Publication number Publication date
AU1593697A (en) 1997-08-20
NO983215D0 (no) 1998-07-13
NO983215L (no) 1998-09-17
WO1997026917A1 (fr) 1997-07-31

Similar Documents

Publication Publication Date Title
US4474763A (en) Skin preparation
DE69001730T2 (de) Pastenfoermige, waesserige pharmazeutische zusammensetzungen.
DE69636342T2 (de) Liponsäure in topischen mittel
DE69732977T2 (de) Stabilisierte ascorbylzusammensetzungen
US5741496A (en) Process for the treatment of skins having dry areas and greasy areas
USRE33845E (en) Novel skin tanning composition
GB2130486A (en) Anti-acne compositions based on benzoyl peroxide
EP0138262B1 (fr) Composition pour le traitement des affections de la peau et son usage
JP3489703B2 (ja) 微細エマルション組成物
KR20140146047A (ko) 튼살방지 스킨크림, 이에 대한 제법 및 사용법
JP3432848B2 (ja) 養毛剤
US5032408A (en) Composition for treatment of skin affections and process for its preparation
JPH0624953A (ja) 抗紅斑活性を持つ組成物の化粧品的使用と 対応する組成物
WO1997026917A1 (fr) Composition pour traiter les affections de la peau et procede de preparation de ladite composition
JPH0751491B2 (ja) 生薬配合乳化化粧料
AU769079B2 (en) Topical formulations comprising skin penetration agents and the use thereof
SK15142000A3 (sk) Kozmetické a farmaceutické krémy vo forme emulzie olej vo vode
JP2008273941A (ja) アダパレン含有外用剤組成物
KR100305186B1 (ko) 피지조절능및화장지속성이우수한실리콘유화형수용성젤화장료조성물
EP0914817A1 (fr) Composition d'onguent pour le mamelon
EP0383162A1 (fr) Application d'un mélange de substances actives pour le traitement des maladies rhumatismales
EP0124665B1 (fr) Compositions dermatologiques
JPH08165230A (ja) 化粧料
SU878292A1 (ru) Крем дл кожи
RU2083198C1 (ru) Крем для лица

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020801